Now that cash-rich Argenx has AbbVie fully onboard and a pipeline-in-a-product opportunity in efgartigimod moving smoothly through the clinic, the Belgian biotech is in for an interesting couple of years.
With AbbVie Inc. licensing a preclinical immuno-oncology drug, and strong data backing its lead candidate efgartigimod, argenx SE of Belgium's antibody technology platform has been validated.
The AbbVie deal, announced Aug. 22, saw the US major has exercised an option it took out in April 2016...
The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.
The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.
Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.
Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?
The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.
The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.
First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.
